Application of Next-generation Sequencing Detecting Gene Mutation in Myelodysplastic Syndromes: Current Situation and Problems
-
摘要:
二代测序技术检测基因突变已被推荐为疑似骨髓增生异常综合征（MDS）患者的必检项目。近年来，基于基因突变界定了一系列MDS前驱性疾病、MDS伴SF3B1新亚型和加入基因突变的预后积分系统，基因突变指导下的治疗策略的制定和调整也已形成初步共识。现阶段我国二代测序技术亟待规范化，未来整合组学在临床的应用定将开启MDS个体化医疗新时代。
Abstract:The next-generation sequencing detecting gene mutation has been recommended for the routine diagnosis of suspicious myelodysplastic symdromes patients. Recently, several pre-MDS conditions, a new subtype MDS with SF3B1, gene mutations integrated prognosis scores and gene mutations-based clinical decision-making and treatment choice were proposed. Nowadays, it is a big problem to standardize the generation, analysis, clinical interpretation and reporting of NGS data in China. It will open new horizons for individualized medicine of patients with MDS in the future by implementing integrated genomics into the diagnostic and treatment algorithms.
-
Key words:
- Next-generation sequencing /
- Myelodysplastic syndromes /
- Gene mutations
-
[1] 肖志坚. 骨髓增生异常综合征诊断的方法学: 现况与问题[J]. 国际输血及血液学杂志, 2019, 42(2): 93-97. doi: 10.3760/cma.j.issn.1673-419X.2019.02.001 Xiao ZJ. State of the art: approaches for the diagnosis of myelodysplastic syndromes[J]. Guo Ji Shu Xue Ji Xue Ye Xue Za Zhi, 2019, 42(2): 93-97. doi: 10.3760/cma.j.issn.1673-419X.2019.02.001
[2] 肖志坚. 骨髓增生异常综合征的昨天、今天和明天[J]. 国际输血及血液学杂志, 2020, 43(3): 185-189. doi: 10.3760/cma.j.cn511693-20200326-00072 Xiao ZJ. Myelodysplastic syndromes: yesterday, today and tomorrow[J]. Guo Ji Shu Xue Ji Xue Ye Xue Za Zhi, 2020, 43(3): 185-189. doi: 10.3760/cma.j.cn511693-20200326-00072
[3] 肖志坚. 我国骨髓增生异常综合征的诊治现况及挑战[J]. 内科理论与实践, 2020, 15(5): 281-284. Xiao ZJ. Current situation and challenges of diagnosis and treatment of myelodysplastic syndromes in China[J]. Nei Ke Li Lun Yu Shi Jian, 2020, 15(5): 281-284.
[4] Li MM, Datto M, Duncavage EJ, et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists[J]. J Mol Diagn, 2017, 19(1): 4-23. doi: 10.1016/j.jmoldx.2016.10.002
[5] Palomo L, Ibáñez M, Abáigar M, et al. Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia[J]. Br J Haematol, 2020, 188(5): 605-622. doi: 10.1111/bjh.16175
[6] Spaulding TP, Stockton SS, Savona MR. The evolving role of next generation sequencing in myelodysplastic syndromes[J]. Br J Haematol, 2020, 188(2): 224-239. doi: 10.1111/bjh.16212
[7] Fenaux P, Haase D, Santini V, et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2021, 32(2): 142-156. doi: 10.1016/j.annonc.2020.11.002
[8] Killick SB, Ingram W, Culligan D, et al. British Society for Haematology guidelines for the management of adult myelodysplastic syndromes[J]. Br J Haematol, 2021, 194(2): 267-281. doi: 10.1111/bjh.17612
[9] Killick SB, Wiseman DH, Quek L, et al. British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic Syndromes[J]. Br J Haematol, 2021, 194(2): 282-293 doi: 10.1111/bjh.17621
[10] 中华医学会血液学分会. 骨髓增生异常综合征中国诊断与治疗指南(2019年版)[J]. 中华血液学杂志, 2019, 40(2): 89-97. Chinese society of hematology, Chinese medical association. Chinese guidelines for diagnosis and treatment of myelodysplastic syndromes(2019)[J]. Zhonghua Xue Ye Xue Za Zhi, 2019, 40(2): 89-97.
[11] Valent P, Orazi A, Steensma DP, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes(MDS) and potential pre-MDS conditions[J]. Oncotarget, 2017, 8(43): 73483-73500. doi: 10.18632/oncotarget.19008
[12] Bejar, R. CHIP, ICUS, CCUS and other four-letter words[J]. Leukemia, 2017, 31(9): 1869-1871. doi: 10.1038/leu.2017.181
[13] Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1-mutant MDS as a distinct diseasesubtype: a proposal from the International Working Group for the Prognosis of MDS[J]. Blood, 2020, 136(2): 157-170. doi: 10.1182/blood.2020004850
[14] Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes[J]. Nat Med, 2020, 26(10): 1549-1556. doi: 10.1038/s41591-020-1008-z
[15] Welch JS, Petti AA, Miller CA, et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes[J]. N Engl J Med, 2016, 375(21): 2023-2036. doi: 10.1056/NEJMoa1605949
[16] Uy GL, Duncavage EJ, Chang GS, et al. Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy[J]. Leukemia, 2017, 31(4): 872-881. doi: 10.1038/leu.2016.282
[17] Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes[J]. N Engl J Med, 2020, 382(2): 140-151. doi: 10.1056/NEJMoa1908892
[18] 张喻堤, 徐泽锋, 秦铁军, 等. 环孢素A联合达那唑±沙利度胺治疗原始细胞不增高骨髓增生异常综合征的疗效及其影响因素分析[J]. 中华血液学杂志, 2021, 42(5): 376-382. Zhang YD, Xu ZF, Qin TJ, et al. Prognostic factors of cyclosporine A combined with danazol with or without thalidomide in myelodysplastic syndrome treatment with low-percentage bone marrow blasts[J]. Zhonghua Xue Ye Xue Za Zhi, 2021, 42(5): 376-382.
[19] 陈佳, 曲士强, 秦铁军, 等. 来那度胺治疗伴DDX41胚系突变骨髓增生异常综合征伴原始细胞增多一例报告并文献复习[J]. 中华血液学杂志, 2020, 41(10): 857-860. doi: 10.3760/cma.j.issn.0253-2727.2020.10.012 Chen J, Qu SQ, Qin TJ, et al. Lenalidomide for myelodysplastic syndrome with excess blasts with germline DDX41 mutation: a case report and literatures review[J]. Zhonghua Xue Ye Xue Za Zhi, 2020, 41(10): 857-860. doi: 10.3760/cma.j.issn.0253-2727.2020.10.012
[20] 李世俊, 齐军元. 高危骨髓增生异常综合征的治疗[J]. 肿瘤防治研究, 2020, 47(12): 996-1002. doi: 10.3971/j.issn.1000-8578.2020.20.0412 Li SJ, Qi JY. Treatment of High-risk Myelodysplastic Syndrome[J]. Zhong Liu Fang Zhi Yan Jiu, 2020, 47(12): 996-1002. doi: 10.3971/j.issn.1000-8578.2020.20.0412
[21] 中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会, 中华医学会病理学分会. 二代测序技术在血液肿瘤中的应用中国专家共识(2018版)[J]. 中华血液学杂志, 2018, 39(11): 881-886. doi: 10.3760/cma.j.issn.0253-2727.2018.11.001 Hematology Oncology Committee of China Anti-cancer Association, Chinese Society of hematology Chinese Medical Association, Chinese Society of pathology Chinese Medical Association. Expert Consensus on the Application of Next-Generation Sequencing in Hematological Neoplasms (2018)[J]. Zhonghua Xue Ye Xue Za Zhi, 2018, 39(11): 881-886. doi: 10.3760/cma.j.issn.0253-2727.2018.11.001
[22] Huang H, Wu J, Qin T, et al. Is race important in genomic classification of hematological neoplasms?[J]. Hematol Oncol, 2021. Online ahead of print.
[23] Brierley CK, Mead AJ. Single-cell sequencing in hematology[J]. Curr Opin Oncol, 2020, 32(2): 139-145. doi: 10.1097/CCO.0000000000000613
下载:
